Clinical trials in nuclear medicine. Sorted by date of last update.
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants with Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1
Last update: October 14
Phase I Study of [Lu-177]Lu-NNS309 in Patients with Pancreatic, Lung, Breast and Colorectal Cancers
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
A Study of Lu-177-FAP-2286 in Advanced Solid Tumors (LuMIERE)
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (Lu-177) Vipivotide Tetraxetan in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 2
Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Last update: October 10
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients with Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
Phase 4
Lu-177-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)
Phase 3
Last update: October 9